Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238911 · ClinicalTrials.gov registry record · Phase 3
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
A Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
- 16
- Study locations
NCT03238911: Completed Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S.
NCT03238911 is a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia that has completed, run by Pharmacosmos A/S. The registered enrollment target is 123 participants, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (35% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03238911, a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
- 16
- Study locations
Study Summary
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
Primary Outcome
Safety The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.
Conditions Studied
Interventions
- DRUG Ferric carboxymaltose
- DRUG Iron isomaltoside/ferric derisomaltose
Study Locations (16)
Florida
- Pharmacosmos Investigational Site - Clearwater
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site 1 - Miami
- Pharmacosmos Investigational Site 2 - Miami
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site - Miami
California
- Pharmacosmos Investigational Site - Los Angeles
- Pharmacosmos Investigational Site - Sacramento
- Pharmacosmos Investigational Site - Santa Ana
Indiana
- Pharmacosmos Investigational Site - Indianapolis
Kansas
- Pharmacosmos Investigational Site - Wichita
Louisiana
- Pharmacosmos Investigational Site - Metairie
Pennsylvania
- Pharmacosmos Investigational Site - Lancaster
Texas
- Pharmacosmos Investigational Site - Houston
Utah
- Pharmacosmos Investigational Site - Orem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2018-06-19 |
| Phase | Phase 3 |
What the finished NCT03238911 record still lists
NCT03238911 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Ferric carboxymaltose is the first listed.
NCT03238911 lists 16 locations in 9 states (Florida, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT03238911 about?
NCT03238911 is a clinical study titled "Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia". The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
What is the current status of trial NCT03238911?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2017-10-24. Estimated completion is 2018-06-19.
What conditions does trial NCT03238911 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia.
What interventions are being tested in trial NCT03238911?
The interventions under investigation include: Ferric carboxymaltose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT03238911?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03238911 being conducted?
This trial has 16 study locations across California, Florida, Indiana, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03238911's enrollment target sits among peer trials
123 6th of 24 higher than 19 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
-
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI